Mimedx (MDXG) Net Cash Flow Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.52% |
| Dec 31, 2025 | 30.22% |
| Sep 30, 2025 | -17.68% |
| Jun 30, 2025 | 34.07% |
| Mar 31, 2025 | 16.32% |
| Dec 31, 2024 | 21.62% |
| Sep 30, 2024 | 54.17% |
| Jun 30, 2024 | -20.71% |
| Mar 31, 2024 | -14.90% |
| Dec 31, 2023 | 67.72% |
| Sep 30, 2023 | 77.01% |
| Jun 30, 2023 | -16.11% |
| Mar 31, 2023 | -35.85% |
| Dec 31, 2022 | 20.43% |
| Sep 30, 2022 | 15.61% |
| Jun 30, 2022 | -16.99% |
| Mar 31, 2022 | -26.89% |
| Dec 31, 2021 | -22.92% |
| Sep 30, 2021 | 24.78% |
| Jun 30, 2021 | -50.39% |
| Mar 31, 2021 | 3.71% |
| Dec 31, 2020 | -1.83% |
| Sep 30, 2020 | 90.12% |
| Jun 30, 2020 | -123.82% |
| Mar 31, 2020 | -14.54% |
| Dec 31, 2019 | -106.33% |
| Sep 30, 2019 | -18.64% |
| Jun 30, 2019 | 82.35% |
| Mar 31, 2019 | -73.68% |
| Dec 31, 2018 | -72.21% |
| Sep 30, 2018 | -17.36% |
| Jun 30, 2018 | 68.73% |
| Mar 31, 2018 | 0.14% |
| Dec 31, 2017 | -41.80% |
| Sep 30, 2017 | -33.35% |
| Jun 30, 2017 | 116.27% |
| Mar 31, 2017 | -26.01% |
| Dec 31, 2016 | 32.45% |
| Sep 30, 2016 | -41.10% |
| Jun 30, 2016 | 71.01% |
| Mar 31, 2016 | -110.90% |